Cybin Inc. (CYBN)
USD 9.46
(-0.11%)
USD 9.46
(-0.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -208.7 Million CAD | -289.07% |
| 2022 | -53.64 Million CAD | 16.22% |
| 2021 | -64.02 Million CAD | -4044.08% |
| 2020 | -1.54 Million CAD | 0.0% |
| 2019 | -1.54 Million CAD | -391.53% |
| 2018 | -314.32 Thousand CAD | 27.43% |
| 2017 | -433.1 Thousand CAD | -0.07% |
| 2016 | -432.81 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -183.06 Million CAD | 12.28% |
| 2023 Q3 | -38.63 Million CAD | -113.23% |
| 2023 FY | -208.7 Million CAD | -289.07% |
| 2023 Q1 | -42.46 Million CAD | -155.28% |
| 2023 Q4 | -208.7 Million CAD | -440.21% |
| 2023 Q2 | -18.11 Million CAD | 57.33% |
| 2022 Q2 | -29.93 Million CAD | 29.49% |
| 2022 FY | -53.64 Million CAD | 16.22% |
| 2022 Q4 | -16.63 Million CAD | 26.11% |
| 2022 Q3 | -22.51 Million CAD | 24.81% |
| 2022 Q1 | -42.46 Million CAD | 20.84% |
| 2021 Q1 | -55.07 Million CAD | 13.98% |
| 2021 FY | -64.02 Million CAD | -4044.08% |
| 2021 Q4 | -53.64 Million CAD | 15.63% |
| 2021 Q3 | -63.58 Million CAD | -58.24% |
| 2021 Q2 | -40.17 Million CAD | 27.05% |
| 2020 FY | -1.54 Million CAD | 0.0% |
| 2020 Q3 | -39.92 Million CAD | -19245.35% |
| 2020 Q2 | -206.35 Thousand CAD | 97.32% |
| 2020 Q1 | -7.69 Million CAD | 0.0% |
| 2020 Q4 | -64.02 Million CAD | -60.38% |
| 2019 FY | -1.54 Million CAD | -391.53% |
| 2018 FY | -314.32 Thousand CAD | 27.43% |
| 2017 FY | -433.1 Thousand CAD | -0.07% |
| 2016 FY | -432.81 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | -4121.299% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -5370.537% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 295.325% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | -179.895% |
| Azitra, Inc. | -910.04 Thousand USD | -22833.117% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | -4824.515% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 17902.787% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 4123.54% |
| CEL-SCI Corporation | 9.42 Million USD | 2314.096% |
| iBio, Inc. | -9.75 Million USD | -2040.523% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | -542.355% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | -2818.611% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -16192.037% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 47700.378% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -53413.077% |
| NanoViricides, Inc. | -4.79 Million USD | -4249.951% |
| Oragenics, Inc. | -3.17 Million USD | -6481.971% |
| BiomX Inc. | -772 Thousand USD | -26933.808% |
| BiomX Inc. | -772 Thousand USD | -26933.808% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 7984.435% |
| Palatin Technologies, Inc. | -8.93 Million USD | -2235.232% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 1606.092% |